Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes

Eye volume 37, pages 2535–2541 (2023)Cite this article

Subjects

Abstract

Objectives

To determine 36-month efficacy and safety outcomes of the PRESERFLO Microshunt implant in the treatment of refractory uveitic glaucoma.

Methods

Consecutive patients with uncontrolled uveitic glaucoma despite maximum medical treatment received PRESERFLO Microshunt implant with mitomycin C (MMC) in a tertiary referral glaucoma practice. Efficacy and safety outcomes data were collected at month 6, 12, 24, and 36, postoperatively.

The primary outcome was surgical success, defined as intraocular pressure (IOP) between 5 and 21 mmHg or > 20% reduction from baseline, and absence of criteria for surgical failure. Secondary outcomes were IOP, visual acuity (VA), use of glaucoma medical therapy, surgical complications, rate of reoperation for glaucoma.

Results

21 eyes of 21 patients were included. The mean rate of success was 0.74 (95%CI 0.48–0.88), 0.68 (0.43–0.84), 0.47 (0.25–0.67), and 0.47 (0.25–0.67, at 6, 12, 24, and 36 months postoperatively, respectively. The mean IOP decreased by 30.7% (95% CI 13.7–47.7), 26.5% (95% CI 3.2–49.8), 33.5% (95% CI 21.8–45.3), and 30.1% (95% CI 7.2–52.9) from baseline at postoperative month 6, 12, 24, and 36, respectively (p < 0.001). The mean ± SD number of glaucoma medications decreased from 4.1 ± 0.9 to 0.9 ± 1.2 at the final follow up (p = 0.0005). No sight-threatening complications were reported by 36 months.

Conclusions

Three-year results of the PRESERFLO Microshunt implant demonstrated favourable efficacy and safety profile in the treatment of refractory uveitic glaucoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Kaplan-Meier survival curve for overall cumulative surgical success.
Fig. 2: Kaplan-Meier survival curve for overall cumulative surgical success- impact of ethnicity.
Fig. 3: Kaplan-Meier survival curve for overall cumulative surgical success- impact of prior cataract surgery.
Fig. 4: Intraocular pressure over follow-up.

Similar content being viewed by others

Data availability

The data that support the findings of this study are available from the corresponding author, KB, upon reasonable request.

References

  1. Al-Ani HH, Sims JL, Tomkins-Netzer O, Lightman S, Niederer RL. Vision loss in anterior uveitis. Br J Ophthalmol. 2020;104:1652–7.

    Article  PubMed  Google Scholar 

  2. Aman R, Engelhard SB, Bajwa A, Patrie J, Reddy AK. Ocular hypertension and hypotony as determinates of outcomes in uveitis. Clin Ophthalmol. 2015;9:2291–8.

    PubMed  PubMed Central  Google Scholar 

  3. Sng CCA, Ang M, Barton K. Uveitis and glaucoma: new insights in the pathogenesis and treatment. Prog Brain Res. 2015;221:243–69.

    Article  PubMed  Google Scholar 

  4. Liu X, Kelly SR, Montesano G, Bryan SR, Barry RJ, Keane PA, et al. Evaluating the Impact of Uveitis on Visual Field Progression Using Large-Scale Real-World Data. Am J Ophthalmol. 2019;207:144–50.

    Article  PubMed  Google Scholar 

  5. Din NM, Talat L, Isa H, Tomkins-Netzer O, Barton K, Lightman S. Difference in glaucoma progression between the first and second eye after consecutive bilateral glaucoma surgery in patients with bilateral uveitic glaucoma. Graefe’s Arch Clin Exp Ophthalmol. 2016;254:2439–48.

    Article  Google Scholar 

  6. Ho CL, Wong EYM, Walton DS. Goniosurgery for glaucoma complicating chronic childhood uveitis. Arch Ophthalmol (Chic, Ill 1960) 2004;122:838–44.

    Article  Google Scholar 

  7. Heinz C, Koch JM, Zurek-Imhoff B, Heiligenhaus A. Prevalence of uveitic secondary glaucoma and success of nonsurgical treatment inadults and children in a tertiary referral center. Ocul Immunol Inflamm. 2009;17:243–8.

    Article  PubMed  Google Scholar 

  8. Wang Q, Wang J, Fortin E, Hamel P. Trabeculotomy in the Treatment of Pediatric Uveitic Glaucoma. J Glaucoma. 2016;25:744–9.

    Article  CAS  PubMed  Google Scholar 

  9. Ceballos EM, Beck AD, Lynn MJ. Trabeculectomy with antiproliferative agents in uveitic glaucoma. J Glaucoma. 2002;11:189–96.

    Article  PubMed  Google Scholar 

  10. Kaburaki T, Koshino T, Kawashima H, Numaga J, Tomidokoro A, Shirato S, et al. Initial trabeculectomy with mitomycin C in eyes with uveitic glaucoma with inactive uveitis. Eye. 2009;23:1509–17.

    Article  CAS  PubMed  Google Scholar 

  11. Papadaki TG, Zacharopoulos IP, Pasquale LR, Christen WB, Netland PA, Foster CS. Long-term results of Ahmed glaucoma valve implantation for uveitic glaucoma. Am J Ophthalmol. 2007;144:62–69.

    Article  PubMed  Google Scholar 

  12. Ceballos EM, Parrish RK, Schiffman JC. Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Ophthalmology 2002;109:2256–60.

    Article  PubMed  Google Scholar 

  13. Borisuth NS, Phillips B, Krupin T. The risk profile of glaucoma filtration surgery. Curr Opin Ophthalmol. 1999;10:112–6.

    Article  CAS  PubMed  Google Scholar 

  14. Krishna R, Godfrey DG, Budenz DL, Escalona-Camaano E, Gedde SJ, Greenfield DS, et al. Intermediate-term outcomes of 350-mm(2) Baerveldt glaucoma implants. Ophthalmology 2001;108:621–6.

    Article  CAS  PubMed  Google Scholar 

  15. Landers J, Martin K, Sarkies N, Bourne R, Watson P. A twenty-year follow-up study of trabeculectomy: risk factors and outcomes. Ophthalmology 2012;119:694–702.

    Article  PubMed  Google Scholar 

  16. Chaku M, Bajwa A, Lee JK, Netland PA. Treatment of Uveitis and Outcomes of Glaucoma Drainage Implant Surgery: A Meta-Analysis. Ocul Immunol Inflamm. 2020;28:833–8.

    Article  PubMed  Google Scholar 

  17. Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma. Clin Exp Ophthalmol. 2017;45:393–400.

    Article  PubMed  Google Scholar 

  18. Sng CC, Wang J, Hau S, Htoon HM, Barton K. XEN-45 collagen implant for the treatment of uveitic glaucoma. Clin Exp Ophthalmol. 2018;46:339–45.

    Article  PubMed  Google Scholar 

  19. Kerr NM, Wang J, Sandhu A, Harasymowycz PJ, Barton K. Ab Interno Gel Implant-associated Bleb-related Infection. Am J Ophthalmol. 2018;189:96–101.

    Article  PubMed  Google Scholar 

  20. Gedde SJ, Chen PP, Heuer DK, Singh K, Wright MM, Feuer WJ, et al. The primary tube versus trabeculectomy study: Methodology of a multicenter randomized clinical trial comparing tube shunt surgery and trabeculectomy with Mitomycin C. Ophthalmology 2018;125:774–81.

    Article  PubMed  Google Scholar 

  21. Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK 2nd, Heuer DK, Brandt JD. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005;140:275–87.

    Article  PubMed  Google Scholar 

  22. Batlle JF, Fantes F, Riss I, Pinchuk L, Alburquerque R, Kato YP, et al. Three-year follow-up of a novel aqueous humor microshunt. J Glaucoma. 2016;25:e58–65.

    Article  PubMed  Google Scholar 

  23. Schlenker MB, Durr GM, Michaelov E, Ahmed IIK. Intermediate outcomes of a novel standalone Ab Externo SIBS microshunt with Mitomycin C. Am J Ophthalmol. 2020;215:141–53.

    Article  CAS  PubMed  Google Scholar 

  24. Bhayani R, Martinez de la Casa JM, Figus M, Klabe K, Rabiolo A, Mercieca K. Short-term safety and efficacy of Preserflo™ Microshunt in glaucoma patients: A multicentre retrospective cohort study. Eye (Lond). 2022;12:1–6.

    Google Scholar 

  25. Broadway DC, Bates AK, Lightman SL, Grierson I, Hitchings RA. The importance of cellular changes in the conjunctiva of patients with uveitic glaucoma undergoing trabeculectomy. Eye (Lond). 1993;7:495–501.

    Article  PubMed  Google Scholar 

  26. Ni M, Chan CC, Nussenblatt RB, Li SZ, Mao W. Iris inflammatory cells, fibronectin, fibrinogen, and immunoglobulin in various ocular diseases. Arch Ophthalmol (Chic, Ill 1960) 1988;106:392–5.

    Article  CAS  Google Scholar 

  27. Chow A, Burkemper B, Varma R, Rodger DC, Rao N, Richter GM. Comparison of surgical outcomes of trabeculectomy, Ahmed shunt, and Baerveldt shunt in uveitic glaucoma. J Ophthalmic Inflamm Infect. 2018;8:9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Vinod K, Gedde SJ, Feuer WJ, Panarelli JF, Chang TC, Chen PP, et al. Practice preferences for glaucoma surgery: A survey of the American glaucoma society. J Glaucoma. 2017;26:687–93.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Do AT, Parikh H, Panarelli JF. Subconjunctival microinvasive glaucoma surgeries: An update on the Xen gel stent and the PreserFlo MicroShunt. Curr Opin Ophthalmol. 2020;31:132–8.

    Article  PubMed  Google Scholar 

Download references

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Glaucoma Service, Moorfields Eye Hospital, 162 City Rd, London, EC1V 2PD, UK

    Giacinto Triolo, Jing Wang, Soledad Aguilar-Munoa, Hari Jayaram & Keith Barton

  2. NIHR Moorfields Biomedical Research Centre, 162 City Rd, London, EC1V 2PD, UK

    Hari Jayaram

  3. Institute of Ophthalmology, University College London, 11-43 Bath St, London, EC1V 9EL, UK

    Hari Jayaram & Keith Barton

Authors
  1. Giacinto Triolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soledad Aguilar-Munoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hari Jayaram
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keith Barton
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GT: Conceptualization, Methodology, Formal analysis, Investigation, Data curation, Writing – Original draft, Writing – Review & Editing; JW: Conceptualization, Investigation; Soledad SA-M: Methodology, Investigation, Data curation; HJ: Formal analysis, Writing – Review & Editing; KB: Conceptualization, Writing – Review & Editing; Supervision.

Corresponding author

Correspondence to Keith Barton.

Ethics declarations

Competing interests

Keith Barton lectured and consulted for Santen, receiving compensation. The rest of co-authors declare no competing financial interests related to the topic of this paper.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Triolo, G., Wang, J., Aguilar-Munoa, S. et al. Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes. Eye 37, 2535–2541 (2023). https://doi.org/10.1038/s41433-022-02368-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41433-022-02368-w

This article is cited by

Search

Advanced search

Quick links